AFM-30a is an experimental drug which was the first selective inhibitor to be developed of the enzyme peptidylarginine deiminase 2 (PAD2). It has been used to investigate the role of PAD2 in various inflammatory conditions and development of cancers. It was found to be active against pulmonary fibrosis in a mouse model.
See also BB-Cl-Amidine GSK484 JBI-589
References